 Peter Moore
Concepts (92)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Plasminogen | 2 | 2025 | 27 | 1.120 |
Why?
| | Fibrinolytic Agents | 3 | 2025 | 297 | 1.050 |
Why?
| | Thrombolytic Therapy | 2 | 2025 | 164 | 1.030 |
Why?
| | Factor XIII | 1 | 2025 | 15 | 0.910 |
Why?
| | Empyema, Pleural | 1 | 2025 | 13 | 0.910 |
Why?
| | Cathepsins | 1 | 2025 | 24 | 0.900 |
Why?
| | Tissue Plasminogen Activator | 6 | 2025 | 248 | 0.900 |
Why?
| | Fibrinolysis | 3 | 2025 | 164 | 0.890 |
Why?
| | Pleural Effusion | 1 | 2025 | 59 | 0.860 |
Why?
| | Folate Receptor 2 | 1 | 2023 | 8 | 0.770 |
Why?
| | Blood Coagulation Disorders | 1 | 2025 | 198 | 0.760 |
Why?
| | Wounds and Injuries | 2 | 2025 | 961 | 0.610 |
Why?
| | Pneumonia | 1 | 2023 | 636 | 0.500 |
Why?
| | Helsinki Declaration | 1 | 2009 | 1 | 0.300 |
Why?
| | Emergencies | 1 | 2009 | 174 | 0.270 |
Why?
| | Erythrocyte Transfusion | 1 | 2010 | 225 | 0.270 |
Why?
| | Informed Consent | 1 | 2009 | 198 | 0.260 |
Why?
| | Research | 1 | 2009 | 430 | 0.230 |
Why?
| | Streptokinase | 1 | 2025 | 9 | 0.230 |
Why?
| | Hemothorax | 1 | 2025 | 16 | 0.220 |
Why?
| | Pneumonia, Viral | 2 | 2020 | 389 | 0.220 |
Why?
| | Coronavirus Infections | 2 | 2020 | 383 | 0.220 |
Why?
| | Sex Characteristics | 1 | 2010 | 782 | 0.210 |
Why?
| | Thoracic Injuries | 1 | 2025 | 71 | 0.210 |
Why?
| | History, 20th Century | 1 | 2025 | 328 | 0.210 |
Why?
| | Thrombelastography | 1 | 2025 | 192 | 0.200 |
Why?
| | Cysteine | 1 | 2025 | 211 | 0.200 |
Why?
| | Lipopolysaccharides | 2 | 2024 | 858 | 0.190 |
Why?
| | Adenocarcinoma | 1 | 2010 | 925 | 0.190 |
Why?
| | Membrane Glycoproteins | 1 | 2024 | 499 | 0.180 |
Why?
| | Pancreatic Neoplasms | 1 | 2010 | 928 | 0.170 |
Why?
| | Lung Injury | 1 | 2024 | 244 | 0.170 |
Why?
| | Shock, Hemorrhagic | 1 | 2024 | 199 | 0.170 |
Why?
| | Pulmonary Fibrosis | 1 | 2024 | 395 | 0.160 |
Why?
| | Sequence Analysis, RNA | 1 | 2023 | 442 | 0.160 |
Why?
| | Betacoronavirus | 2 | 2020 | 288 | 0.160 |
Why?
| | Monocytes | 1 | 2023 | 539 | 0.150 |
Why?
| | Anti-Glomerular Basement Membrane Disease | 1 | 2019 | 4 | 0.150 |
Why?
| | Venous Thromboembolism | 1 | 2024 | 328 | 0.150 |
Why?
| | Hemoptysis | 1 | 2019 | 35 | 0.150 |
Why?
| | Salvage Therapy | 1 | 2020 | 165 | 0.140 |
Why?
| | Macrophages | 2 | 2024 | 1507 | 0.140 |
Why?
| | Proteomics | 1 | 2025 | 1188 | 0.140 |
Why?
| | Dyspnea | 1 | 2019 | 250 | 0.130 |
Why?
| | Phenotype | 1 | 2025 | 3155 | 0.120 |
Why?
| | Inflammation | 2 | 2025 | 2878 | 0.110 |
Why?
| | Lung | 2 | 2024 | 4106 | 0.110 |
Why?
| | Humans | 11 | 2025 | 145474 | 0.100 |
Why?
| | Blood Transfusion, Autologous | 1 | 2010 | 18 | 0.080 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2010 | 81 | 0.080 |
Why?
| | Patient Rights | 1 | 2009 | 11 | 0.070 |
Why?
| | Multiple Organ Failure | 1 | 2009 | 120 | 0.070 |
Why?
| | Plasma | 1 | 2010 | 223 | 0.070 |
Why?
| | Middle Aged | 3 | 2025 | 36215 | 0.070 |
Why?
| | Male | 5 | 2025 | 72842 | 0.070 |
Why?
| | Disease Models, Animal | 2 | 2024 | 4560 | 0.060 |
Why?
| | Resuscitation | 1 | 2009 | 310 | 0.060 |
Why?
| | Body Weight | 1 | 2010 | 971 | 0.060 |
Why?
| | Heme Oxygenase (Decyclizing) | 1 | 2005 | 21 | 0.060 |
Why?
| | Blood Substitutes | 1 | 2005 | 27 | 0.060 |
Why?
| | Pancreatic Elastase | 1 | 2025 | 53 | 0.060 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2005 | 132 | 0.060 |
Why?
| | Plasminogen Activator Inhibitor 1 | 1 | 2025 | 85 | 0.050 |
Why?
| | Adult | 2 | 2025 | 40777 | 0.050 |
Why?
| | Eye Proteins | 1 | 2024 | 92 | 0.050 |
Why?
| | Erythrocytes | 1 | 2010 | 748 | 0.050 |
Why?
| | Female | 3 | 2025 | 78844 | 0.050 |
Why?
| | Bleomycin | 1 | 2024 | 255 | 0.050 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2025 | 848 | 0.050 |
Why?
| | Blotting, Western | 1 | 2025 | 1179 | 0.050 |
Why?
| | Fibrosis | 1 | 2024 | 559 | 0.040 |
Why?
| | Macrophages, Alveolar | 1 | 2024 | 373 | 0.040 |
Why?
| | Pandemics | 2 | 2020 | 1707 | 0.040 |
Why?
| | Single-Cell Analysis | 1 | 2024 | 362 | 0.040 |
Why?
| | Mice | 2 | 2024 | 18329 | 0.040 |
Why?
| | Markov Chains | 1 | 2020 | 132 | 0.040 |
Why?
| | Hospitals | 1 | 2024 | 732 | 0.040 |
Why?
| | Endothelium, Vascular | 1 | 2005 | 956 | 0.040 |
Why?
| | United States | 2 | 2020 | 16098 | 0.030 |
Why?
| | Decision Support Techniques | 1 | 2020 | 477 | 0.030 |
Why?
| | Animals | 2 | 2024 | 38030 | 0.030 |
Why?
| | Survival Rate | 1 | 2020 | 2090 | 0.030 |
Why?
| | Respiration, Artificial | 1 | 2020 | 713 | 0.030 |
Why?
| | Mice, Inbred C57BL | 1 | 2024 | 5983 | 0.020 |
Why?
| | Critical Illness | 1 | 2020 | 900 | 0.020 |
Why?
| | Risk Factors | 1 | 2024 | 10885 | 0.020 |
Why?
| | Heme Oxygenase-1 | 1 | 2005 | 76 | 0.010 |
Why?
| | Microcirculation | 1 | 2005 | 142 | 0.010 |
Why?
| | Hemoglobins | 1 | 2005 | 386 | 0.010 |
Why?
| | Analysis of Variance | 1 | 2005 | 1300 | 0.010 |
Why?
| | Up-Regulation | 1 | 2005 | 847 | 0.010 |
Why?
| | Membrane Proteins | 1 | 2005 | 1164 | 0.010 |
Why?
|
|
Moore's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|